FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely immunology, and may be used for reducing eosinophil count in a human body. That is ensured by the parenteral administration of approximately 0.01 mg/kg to approximately 0.25 mg/kg of a monoclonal chimeric humanised antibody or a human antibody which binds to IL-5P and contains an immunoglobulin Fc fragment and is fucose-free; the administered antibody reduces the peripheral blood circulating eosinophil count below the detection threshold, and the circulating eosinophil calculation level remains below the detection threshold for approximately 28 days after antibody dosing.
EFFECT: using the given method leads to fast and prolonged reduction of peripheral blood eosinophils.
9 cl, 14 ex, 31 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF REDUCING BASOPHILS NUMBER | 2014 |
|
RU2618455C2 |
| METHODS FOR REDUCING EXACERBATION RATES OF ASTHMA USING OF BENRALIZUMAB | 2014 |
|
RU2676333C2 |
| METHODS FOR INCREASING FORCED EXPIRATORY VOLUME IN ASTHMATIC PATIENTS USING BENRALIZUMAB | 2014 |
|
RU2703568C2 |
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
| DIAGNOSTICS AND TREATMENT METHODS ASSOCIATED WITH TH2 INHIBITION | 2011 |
|
RU2737245C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST | 2018 |
|
RU2793745C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS FOR NORMALIZING ASTHMA SYMPTOMS USING BENRALIZUMAB | 2014 |
|
RU2728578C2 |
| THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES | 2019 |
|
RU2795180C2 |
| ANGIOGENESIS PROMOTING AGENT AND METHODS FOR ITS USE | 2018 |
|
RU2771982C2 |
